Koers InMed Pharmaceuticals Inc Deutsche Boerse AG
Aandelen
CA13764X1069
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- EUR | - |
Omzet 2024 * | 7,3 mln. 5,35 mln. 4,94 mln. | Omzet 2025 * | 9,12 mln. 6,69 mln. 6,17 mln. | Marktkapitalisatie | 2,55 mln. 1,87 mln. 1,73 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,35 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,28 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,01% |
Recentste transcriptie over InMed Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Chief Operating Officer | - | 05-11-18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11-02-22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Andrew Hull
CHM | Chairman | 61 | 12-09-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |